Assessing the impact of citicoline on the efficiency of rehabilitation measures in patients with ischemic stroke

Mushba A.V.; Ivanova D.S.; Vinogradov O.I.

doi:https://doi.org/10.17116/jnevro20161162171-75

Mushba A.V.

National Center of Cerebrovascular Disorders of the Pirogov National Centre of Therapy and Surgery

Ivanova D.S.

National Center of Cerebrovascular Disorders of the Pirogov National Centre of Therapy and Surgery

Vinogradov O.I.

Pirogov National Medical and Surgical Center

ORCID: 0000-0002-3847-9366

Assessing the impact of citicoline on the efficiency of rehabilitation measures in patients with ischemic stroke

Authors:

Mushba A.V., Ivanova D.S., Vinogradov O.I.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(2): 71‑75

DOI: 10.17116/jnevro20161162171-75

Read: 4861 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Mushba AV, Ivanova DS, Vinogradov OI. Assessing the impact of citicoline on the efficiency of rehabilitation measures in patients with ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(2):71‑75. (In Russ.)
https://doi.org/10.17116/jnevro20161162171-75

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To evaluate the effect of citicoline on the efficacy of rehabilitation measures in patients with ischemic stroke (IS).

MATERIAL AND METHODS

Sixty patients were examined in the acute period of hemispheric IS. All patients underwent routine comprehensive treatment. The study group included 30 patients who received citicoline within the first 24 hours after IS onset. The control group consisted of 30 patients who were not treated with citicoline. The examination of patients included the assessment of neurological deficit, cognitive functions, P300 evoked potentials, head single photon emission computed tomography.

RESULTS

Six months after the onset of disease, there was a significant improvement in cognitive functions as assessed with the MMSE and MoCa scale, and P300 latency in the main group. There was a trend towards the improvement in the activities of daily living (Barthel index) in patients of the main group compared to the control group. SPECT results showed the improvement in cerebral perfusion in an affected hemisphere: in Broca's area, the rear sections of the upper and middle frontal gyrus, the parietal lobe (p <0.05).

CONCLUSION

Citicoline significantly improves cognitive function, which in turn has a positive effect on the efficacy of remediation and indirectly improves cerebral perfusion in patients with hemispheric IS.

Keywords:

citicoline

ischemic stroke

rehabilitation

cognitive functions

SPECT

Authors:

Mushba A.V.

National Center of Cerebrovascular Disorders of the Pirogov National Centre of Therapy and Surgery

Ivanova D.S.

National Center of Cerebrovascular Disorders of the Pirogov National Centre of Therapy and Surgery

Vinogradov O.I.

Pirogov National Medical and Surgical Center

ORCID: 0000-0002-3847-9366

Close metadata

References:

Sarti C, Rastenyte D, Cepaitis Z, Tuomilehto J. International trends in mortality from stroke, 1968 to 1994. Stroke. 2000;31:1588-1601. https://doi.org/10.1161/01.str.31.7.1588
Skvortsova V.I., Chazova I.E., Stakhovskaya L.V. Secondary prevention of stroke. M.: PAGRI; 2002.
Stroke: diagnosis, treatment, prevention. Edited by Suslina Z.A., Piradov M.A. M.: Medpress-inform; 2008.
Suslina Z.A., Varakin Y.Y. Epidemiological aspects of stroke studies. Time to summarize. Annals of Clinical and Experimental Neurology. 2007;1:2:22-28
Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V. Worldwide stroke incidence and early case fatality reported in 56 population–based studies: a systematic review Lancet Neurol. 2009 Apr;8(4):355-69. https://doi.org/10.1016/S1474-4422(09)70025-0
Howard G, Howard VJ. Stroke incidence, mortality, and prevalence. The prevention of stroke/edited by Philip B. Gorelick and Milton Alter. The Parthenon Publishing Group. 2002. https://doi.org/10.1201/NOE1842141151.ch1
Diseases of the nervous system. Manual for Physicians. Ed. by Yakhno N.N., Shtulman D.R. 2nd edition, revised and supplemented. M. 2001.
Gusev EI, Skvortsova VI, Stakhovskaya LV. Stroke problem in the Russian Federation: time of active joint actions. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2007;107(8):4-10.
Shakhparonova N.V. Complex approach to rehabilitation of patients with cognitive impairment. Medical Bulletin. 2013;17-18:630-631.
Kuznetsov A.N., Vinogradov O.I. Pocket Guide Ischemic Stroke. Diagnostics. Treatment. Prevention. M. 2014.
Ginsberg MD. Neuroprotection for ischemic stroke: past, present and future. Neuropharmacol. 2008;55(3):363-389. https://doi.org/10.1016/j.neuropharm.2007.12.007
Saver JL. Citicoline: update on a promising and widely available agent for neuroprotection and neurorepair. Rev Neurol Dis. 2008;5(4):167-177.
Bustamante A, Giralt D, Garcia-Bonilla L, Campos M, Rosell A, Montaner I. Citicoline in pre-clinical animal models of stroke: a meta-analysis shows the optimal neuroprotective profile and the missing steps for jumping into a stroke clinical trial. J Neurochem. 2012;123(2):217-225. https://doi.org/10.1111/j.1471-4159.2012.07891.x
Fioravanti M, Yanagi M Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD000269. Review. PMID: 15846601
Warach S, Pettigrew LC, Dashe JF, Pullicino P, Lefkowitz DM, Sabounjian L, Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Ann Neurol, 48: 713-722, 2000
Dávalos A, Alvarez-Sabín J, Castillo J, Díez-Tejedor E, Ferro J, Martínez-Vila E, Serena J, Segura T, Cruz VT, Masjuan J, Cobo E, Secades JJ; International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo–controlled study (ICTUS trial). Lancet. 2012; 380(9839:349–357. https://doi.org/10.1016/S0140-6736(12)60813-7
Domashenko MA, Maximova MA, Sergeev DV, Piradov MA Citicoline in the treatment of ischemic disturbances of cerebral circulation. Russian Medical Journal. 2013;30:1540-1542.
Sergeev D.V., Piradov M.A. Citicoline in the treatment of ischemic stroke: new evidence for efficacy. RMJ. 2012;31:1552-1554.
The European Stroke Organisation (ESO) Executive Committee and the ESO Writing Committee. European Stroke Organization Guidelines for Management of Ischaemic Stroke and Transient Ischaemic Attack 2008. Cerebrovasc Dis 2008;25:457–507 https://doi.org/10.1159/000131083
Sobrino T, Rodríguez-González R, Brea D et al. CDP-choline treatment increases circulating endothelial progenitor cells in acute ischemic stroke. Published by Maney Publishing W.S. Maney & Son. Limited Clinical Neuroscience Research Laboratory. 2011;33:6:572-577. https://doi.org/10.1179/016164110X12807570510176
Gutierrez-Fernandez M, Rodriguez-Frutos B, Fuentes B et al. CDP-choline treatment induces brain plasticity markers expression in experimental animal stroke. Neurochemistry Int. 2012;60:310—317. https://doi.org/10.1016/j.neuint.2011.12.015
Milani M. Citicoline as coadiuvant treatment of cognitive impairment in chronic degenerative Central Nervous System diseases and in ischemic stroke SSN 2277-0879. 2013;2:2:13-18.